Synergistic Effect and Safety of [ 177 Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Prior Radiotherapy for Metastatic Castration-Resistant Prostate Cancer (EANM 2026) - Sep 29, 2026 - Abstract #EP-0890; "The combination of EBRT and [177Lu]Lu-PSMA-617 for the treatment of mCRPC did not significantly increase treatment-related adverse effects. Compared with ¹⁷⁷Lu-PSMA-617 monotherapy, the combination therapy improved overall survival in patients with prostate cancer."
Clinical • Metastases • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor
|